Company

Magnet Biomedicine, Inc.

Magnet Biomedicine develops molecular glue medicines for cancer, cardiovascular disease, and immune disorders.

About

Based in Massachusetts, Magnet Biomedicine researches molecular glue medicines for cancer, cardiovascular disease, and immune disorders. Co-founded by David Spiegel, Michael Rosbash, Richa Saxena, and Stuart Schreiber, the company uses biology and proteomics to identify molecular glues for drug targets. In September 2023, it raised USD 50 million in Series A funding co-led by Newpath Partners and ARCH Venture Partners.

1Funding rounds

2Investors

Sign in to see more

Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.

Sign in